”we’re one of the few companies really focusing on optimising the pharmacology of these first generation compounds to develop entirely new therapeutics”
”addressing the intense perceptual effects, and either reducing their duration or tempering them to make the therapies more applicable to a wider patient population”
sound familiar? Just like IHL’s modus operandi around leaning on the de-risked nature of constituent drugs, and focus on combination to not only combine different methods of action but also lower side effects.
IHL Price at posting:
26.0¢ Sentiment: Buy Disclosure: Held
